What 4 new studies reveal about staying on medication, reducing suicide risk, and understanding bipolar biology. Key ...

June 4, 2009 — The latest results from the European First Episode Schizophrenia Trial (EUFEST) show that when it comes to improving cognition in patients with schizophrenia, there is little difference ...

Neither first- nor second-generation antipsychotics show a clear benefit over placebo for preventing or treating delirium in hospitalized adults, and their routine use should be discontinued, ...

A systematic review and network meta-analysis of 68 studies has found no clear evidence that any specific antipsychotic significantly improves cognitive function in patients with schizophrenia ...

A new study analyzing Medicaid databases from 2017 to 2021 has uncovered significant differences in how long-acting injectable (LAI) antipsychotic medications are prescribed to older adults across ...

Teva announces positive real-world outcomes for UZEDY® and TEV-'749 in schizophrenia treatment, highlighting improved adherence and reduced hospital visits. Teva Pharmaceuticals has announced positive ...

When agitated dementia patients wander or shout through the night, families and caregivers understandably feel the need to treat this frightening and potentially dangerous behavior. Antipsychotic ...

—That question formed the basis of a new study from the U.K., which sought to learn more about the risk of tardive dyskinesia (TD)—a persistent, potentially irreversible movement disorder—in children ...

I know first-hand why people go off antipsychotics, and why it is hard to stay on them. I went off of them twice on my own and paid dearly for it. I know many others who go through similar issues, ...